MRG-004A is under clinical development by Shanghai Miracogen and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRG-004A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MRG-004A overview

MRG-004A is under development for the treatment of solid tumors including triple-negative breast cancer, pancreatic cancer and ovarian cancer. The drug candidate is an antibody-drug conjugate which is developed by based on ADC technology. It is administered through intravenous route and acts by targeting tissue factor (TF).

Shanghai Miracogen overview

Shanghai Miracogen., biotechnology company that offers development, clinical research and industrialization of new cancer targeted therapy drugs-the world’s cutting-edge technology Antibody Drug Conjugate (ADC) and innovative antibody anti-tumor drugs

For a complete picture of MRG-004A’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.